Table: Anges -2019 group forecast
Oct 28 (Reuters) -
Anges, Inc.
CONSOLIDATED EARNINGS ESTIMATES
(in billions of yen unless specified)
Full Year to Full Year to
Dec 31, 2019 Dec 31, 2019
LATEST PREVIOUS
FORECAST FORECAST
Sales 335 mln 335 mln
Operating loss 3.30 loss 2.80
Recurring loss 3.30 loss 2.80
Net loss 3.70 loss 2.80
EPS loss 35.33 yen loss 26.74 yen
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001